Pasithea Therapeutics Corp (NASDAQ:KTTA)’s traded shares stood at 0.48 million during the last session, with the company’s beta value hitting 0.65. At the close of trading, the stock’s price was $1.91, to imply a decrease of -10.75% or -$0.23 in intraday trading. The KTTA share’s 52-week high remains $9.25, putting it -384.29% down since that peak but still an impressive -1.05% since price per share fell to its 52-week low of $1.93. The company has a valuation of $2.42M, with an average of 6.25 million shares in intraday trading volume over the past 10 days and average of 1.07 million shares over the past 3 months.
Pasithea Therapeutics Corp (NASDAQ:KTTA) trade information
After registering a -10.75% downside in the last session, Pasithea Therapeutics Corp (KTTA) has traded red over the past five days. The 5-day price performance for the stock is -14.73%, and -36.12% over 30 days. With these gigs, the year-to-date price performance is -39.37%. Short interest in Pasithea Therapeutics Corp (NASDAQ:KTTA) saw shorts transact 11581.0 shares and set a 0.32 days time to cover.
KTTA Dividends
Pasithea Therapeutics Corp has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Pasithea Therapeutics Corp (NASDAQ:KTTA)’s Major holders
Pasithea Therapeutics Corp insiders hold 23.12% of total outstanding shares, with institutional holders owning 2.87% of the shares at 3.73% float percentage. In total, 2.87% institutions holds shares in the company.
We also have Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund as the top two Mutual Funds with the largest holdings of the Pasithea Therapeutics Corp (KTTA) shares. Going by data provided on Nov 30, 2024 , Fidelity Extended Market Index Fund holds roughly 2.96 shares. This is just over 0.23% of the total shares, with a market valuation of $5661.0. Data from the same date shows that the other fund manager holds a little less at 880.0, or 0.07% of the shares, all valued at about 1680.0.
